What to weigh when comparing PRP with bone marrow concentrate drawn from the pelvis

What to know before choosing PRP

Platelet-rich plasma, or PRP, begins with blood taken from your arm and spun. Spinning gathers the blood pieces that form clots, called platelets, into less liquid.

A clinician then puts that liquid into the joint. Some people report relief, but careful studies don’t all find the same benefit.

The blood draw is usually the only collection needed for this choice. Your joint may feel more sore for a while afterward.

Ask how long to rest and when you may return to normal movement. You’ll also want the total cost in writing before you decide.

Neither PRP nor marrow care replaces an exam that looks for the cause. We’d begin with that exam before comparing either procedure.

What to bring when comparing PRP and BMAC

Bone marrow aspirate concentrate, or BMAC, starts with soft tissue drawn from your pelvis, which is spun before a clinician puts the prepared liquid into the joint.

The pelvis must be numbed for the draw and may be tender later. You’ll have another sore area to consider that day.

Bring any X-ray report, a current medicine list, and notes about earlier care. It’s helpful to name one activity you wish to resume.

Ask whether BMAC is expected to ease soreness better than PRP in people like you. Current research hasn’t found better relief with BMAC than with PRP.

Until your visit, choose steady movement and stop if sharp pain begins. There’s no reason to test the joint before someone examines it.

For Chandler patients, QC Kinetix holds consultations about concentrated PRP and biologic therapies, meaning care that medical providers make with drawn blood or marrow collected at the pelvis today.

Sources

1. A meta-analysis of 27 Level I studies (1,042 PRP, 226 BMAC, 1,128 HA patients) found significantly better post-injection WOMAC, VAS and subjective IKDC scores for BOTH PRP and BMAC compared with hyaluronic acid - and NO significant difference between PRP and BMAC on any outcome score. This is the clearest published statement that the two most-marketed orthobiologics perform the same as each other in the knee.

   Belk JW, et al. — Patients With Knee Osteoarthritis Who Receive Platelet-Rich Plasma or Bone Marrow Aspirate Concentrate Injections Have Better Outcomes Than Patients Who Receive Hyaluronic Acid: Systematic Review and Meta-analysis.. Arthroscopy, 2023. DOI: 10.1016/j.arthro.2023.03.001.

2. The largest head-to-head trial of cell-based orthobiologics to date randomised 480 patients with KL II-IV knee OA across four arms: autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, allogeneic umbilical cord tissue-derived MSCs, and a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another or to the corticosteroid control on either co-primary endpoint (VAS pain, KOOS pain), and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events were reported.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.. Nature Medicine, 2023. DOI: 10.1038/s41591-023-02632-w.

3. The 2025 Cochrane review of stem cell injections for knee osteoarthritis pooled 25 randomised trials (1,341 participants) and found that, compared with placebo injection, stem cell injection MAY slightly improve pain (1.2 points better on a 0-10 scale, 7 studies, 445 participants) and function (14.2 points better on a 0-100 scale, 7 studies, 432 participants) up to six months - both rated LOW-certainty evidence, downgraded for indirectness (cell source, preparation and dose varied across studies) and suspected publication bias, since up to three larger RCTs were conducted and withdrawn before reporting results. Radiographic progression was not assessed in any included study.

   Whittle SL, et al. — Stem cell injections for osteoarthritis of the knee.. Cochrane Database of Systematic Reviews, 2025. DOI: 10.1002/14651858.CD013342.pub2.

4. A phase I/II randomized trial (n=26) compared hyaluronic acid with a single or a repeated dose of culture-expanded umbilical cord-derived MSCs. Only the MSC-treated patients improved significantly from baseline, and the repeated-dose group had significantly lower WOMAC pain (1.1 vs 4.3; P=.04) and VAS pain (2.4 vs 22.1; P=.03) than HA at 12 months. No MRI differences were detected and the trial is very small - it is hypothesis-generating, not practice-changing.

   Matas J, et al. — Umbilical Cord-Derived Mesenchymal Stromal Cells (MSCs) for Knee Osteoarthritis: Repeated MSC Dosing Is Superior to a Single MSC Dose and to Hyaluronic Acid in a Controlled Randomized Phase I/II Trial.. Stem Cells Translational Medicine, 2019. DOI: 10.1002/sctm.18-0053.

5. FDA states verbatim of stem cell products, stromal vascular fraction (adipose-derived cells), umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products: 'None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders of blood production, and there are currently NO FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.